In the last number of years, the treatments for inflammatory bowel disease have been rapidly evolving. With the emergence of biologic therapies as the more effective medications for the treatment of moderate to severe ulcerative colitis and Crohn’s disease, understanding the best methods to effectively utilize them to induce and maintain remission is critical for the practicing gastroenterologist. In addition to antitumor necrosis (anti-TNF) agents (infliximab, adalimumab, golimumab, certolizumab) and anti-integrins (vedolizumab and natalizumab), the FDA has recently approved biosimilar anti-TNF agents and ustekinumab, an anti-IL12/IL23 inhibitor.

We are excited that this book, *Treatment of Inflammatory Bowel Disease with Biologics*, provides the reader with expert reviews on important topics pertaining to the use of biologics in inflammatory bowel disease as well their potential complications. The authors were carefully chosen for their expertise in the management of inflammatory bowel disease and their ability to summarize the important concepts.

Drs Alan Moss, Scott Lee, and Byron Vaughn provide expert summaries on the mechanisms of action of the various biologics and the use of anti-TNF therapy in ulcerative colitis and Crohn’s disease. Drs Sarah Flier, Miguel Regueiro, Sunandra Kane, and Bret Lashner review the use anti-TNF in special circumstances when managing IBD: extraintestinal manifestations, postoperative Crohn’s disease, pregnancy and lactation, and the perioperative setting.

Drs Corey Siegel, Mark Osterman, and Cynthia Seow examine the critical topics on the role of combination therapy, therapeutic drug monitoring, and the possible discontinuation of biologics. Complications of biologic therapy are expertly summarized by Drs Joshua Korzenik, Millie Long, and Raymond Cross.

Newer agents, including biosimilars, anti-integrins, and novel therapies, are reviewed by Drs Asher Kornbluth, Francis Farraye, and Fernando Velayos. Finally, Drs Gil Melmed and Jennifer Strople evaluate the quality of care and safety of biologic therapy and use of biologics in pediatrics.
We believe that this book will provide the reader with a thorough review of biologic therapies in inflammatory bowel disease and inform the reader on how to optimize patient care on these medications.

Boston, MA, USA  
Adam S. Cheifetz

Boston, MA, USA  
Joseph D. Feuerstein
Treatment of Inflammatory Bowel Disease with Biologics
Cheifetz, A.S.; Feuerstein, J.D. (Eds.)
2018, XI, 335 p. 22 illus., 19 illus. in color., Hardcover
ISBN: 978-3-319-60275-2